The role of PET imaging in Immuno-oncology
Immunotherapy has shown promising outcomes in multiple cancer types and is considered a breakthrough technology when it comes to anti-cancer therapies within cancer care strategies. Despite the prolonged clinical response achieved, response rate are low and variable. For this reason, the use of biomarkers or more effectively, in vivo imaging biomarkers, like PET probes, has a great potential to improve response evaluation in patients receiving immunotherapy.
What will you learn from the webinar ?
- ImmunoPET for imaging immune responses - 18F labeled agents - By Dr. Jelena Levi
- ImmunoPET: Engineered antibodies for imaging immune responses - By Dr. Anna Wu
Dr. Jelena Levi
PhD Dr. Levi has over 15 years of experience in the field of molecular imaging. Prior to CellSight Technologies she served as Director of Chemistry Core at Canary Center for Early Cancer Detection at Stanford University. Her research is focused on development of targeted imaging agents that can be used in cancer diagnosis and treatment monitoring. She has extensive experience in designing and developing agents for a variety of imaging modalities (PET, optical, photoacoustics).
Dr. Anna M. Wu
PhD Anna M. Wu, PhD, is Professor and Chair, Department of Molecular Imaging and Therapy and Co-Director, Center for Theranostic Studies, Beckman Research of the City of Hope, and Professor in the Department of Radiation Oncology at the City of Hope National Medical Center in Duarte, CA. She also holds the title of Research Professor, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA. Dr. Wu’s research interests include engineered antibodies and proteins for targeting, imaging, and therapeutic applications in cancer and immunology, including the use of SPECT, PET, optical and multimodality approaches. Dr. Wu is the Co-Founder and Chief Scientific Advisor to ImaginAb, Inc.